Managing Adverse Effects in Patients with HER2+ Breast Cancer

Opinion
Video

Harold J. Burstein, MD, PhD, discusses the management of adverse events in patients with HER2+ breast cancer, and the Oncology Brothers provide closing thoughts on the entire discussion.

Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content
Adjuvant Ribociclib/NSAI Yields iDFS Benefit in HR+/HER2– Early Breast Cancer

Adjuvant Ribociclib/NSAI Yields iDFS Benefit in HR+/HER2– Early Breast Cancer

Kyle Doherty
October 17th 2025
Article

Adjuvant ribociclib plus aromatase inhibitors significantly improved invasive disease-free survival in early breast cancer, as shown in the NATALEE trial.

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

The safety profile of tucatinib plus trastuzumab and pertuzumab was consistent with the established profiles of each individual agent.

Tucatinib Regimen Improves PFS in HER2+ Metastatic Breast Cancer

Roman Fabbricatore
October 14th 2025
Article

The safety profile of tucatinib plus trastuzumab and pertuzumab was consistent with the established profiles of each individual agent.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Experts discuss various treatment options for patients with HER2-positive breast cancer, and which would benefit the most based on their characteristics.

Analyzing Trials and Treatments in HER2+ Breast Cancer

Ariana Pelosci
October 11th 2025
Article

Experts discuss various treatment options for patients with HER2-positive breast cancer, and which would benefit the most based on their characteristics.

Data from the phase 3 DESTINY-Breast09 trial presented at the 2025 ASCO Annual Meeting formed the basis of the supplemental NDA.

Japan’s MHLW Receives sNDA for T-DXd Combo in Frontline HER2+ Breast Cancer

Roman Fabbricatore
October 8th 2025
Article

Data from the phase 3 DESTINY-Breast09 trial presented at the 2025 ASCO Annual Meeting formed the basis of the supplemental NDA.